MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for ...

Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in ...

FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients two years of age ...

Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the American Academy of ...

– Substantial and durable reductions in convulsive seizure frequency observed in patients treated with 2 or 3 doses of 70mg followed by 45mg maintenance dosing on top of the best available ...

Safety data over 52 weeks: treatment was well tolerated and consistent with 14-week blinded safety data Preliminary analyses presented at the European Academy of Dermatology & Venereology (EADV) ...

Please provide your email address to receive an email when new articles are posted on . Researchers used data from the GRIPHON study and open-label extension study. The median selexipag dose was 1,000 ...

Jasper Therapeutics (JSPR) announced that it is commencing an open-label extension study in chronic urticarias that will roll over patients from the BEACON and SPOTLIGHT studies upon completion of ...

Ponsegromab treatment led to sustained weight gain and GDF-15 suppression over 64 weeks in cancer-associated cachexia patients. Patients initially on placebo gained weight after switching to ...

The MarketWatch News Department was not involved in the creation of this content. -- Adolescents in a long-term, open-label extension study receiving a twice-daily low dose of repinatrabit achieved ...

Acoramidis showed a 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months compared to placebo in the ATTRibute-CM trial. Continuous acoramidis use resulted in a 48.2% ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and ...